Key takeaways
Soliqua 100/33 (insulin glargine / lixisenatide) and Toujeo (insulin glargine) are both medications that manage diabetes. Soliqua 100/33 is a combination of a long-acting insulin and a GLP-1 receptor agonist. It's only FDA-approved for Type 2 diabetets. Toujeo is a long-acting insulin that treats both Type 1 and Type 2 diabetes. Soliqua 100/33 is injected once daily before the first meal of the day. Toujeo is also injected once daily, but when you inject it can vary, as long as it's around the same time each day. Soliqua 100/33 can cause stomach-related side effects like nausea and diarrhea, while Toujeo may lead to fluid retention and weight gain. Both medications can cause low blood sugar and low potassium levels, but Soliqua 100/33 also carries a risk of pancreatitis and gallbladder problems. Both medications are currently available only as brand-name products.
